Global Antibody Drug Conjugate Market Size Study, by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), by Drugs (Adcetris, Blenrep, Enhertu, Kadcyla, Padcev, Trodelvy), by Technology (Cleavable Linker, Linkerless, Non-Cleavable Linker), by Indication (Blood Cancer, Breast Cancer, Lymphoma, Multiple Myeloma, Urothelial Cancer & Bladder Cancer), by End User (Academic Research Institutes, Biopharmaceutical & Biotechnology Companies, Hospitals, Specialized Cancer Centers) and Regional Forecasts 2022-2032
Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030. The Antibody Drug Conjugate (ADC) Market involves the development, manufacturing, and commercialization of therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissues. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs. However, the complexity of the manufacturing process for ADCs is challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.
The ADC market is experiencing a significant shift towards ErbB2 antibodies (HER2) due to their effectiveness in treating breast and gastric cancer. These ADCs have shown substantial clinical success in targeting the HER2 antigen, which is overexpressed in these cancers. Drugs like Enhertu have become prominent in the oncology field for their targeted therapies, providing improved patient outcomes. The preference for ErbB2 antibodies underscores the market's focus on precision medicine and targeted treatment approaches.
Technological advancements are also shaping the ADC market, with a rising preference for linkerless technology. This technology simplifies the manufacturing process and improves the stability and homogeneity of ADCs. Linkerless ADCs directly conjugate the cytotoxic drug to the antibody, offering streamlined production and potentially enhanced therapeutic efficacy. Additionally, cleavable and non-cleavable linkers continue to play crucial roles, with each offering unique benefits in terms of stability and targeted drug release.
In terms of indications, ADCs are rapidly gaining traction for treating breast cancer. Their ability to target overexpressed receptors, such as HER2, makes them highly effective in managing this prevalent cancer type. Furthermore, ADCs are extensively used for blood cancers, lymphomas, and multiple myeloma, demonstrating their versatility in oncology. These targeted therapies are revolutionizing cancer treatment, providing new hope for patients with previously limited options.
The end-user segment for ADCs is diverse, with significant adoption in academic research institutes, biopharmaceutical and biotechnology companies, hospitals, and specialized cancer centers. Academic research institutes are essential in advancing the understanding of ADC mechanisms and exploring new therapeutic applications. Biopharmaceutical and biotechnology companies are at the forefront of ADC development, investing heavily in R&D to discover novel targets and improve drug-linker technologies. Hospitals and specialized cancer centers play pivotal roles in validating ADC efficacy through clinical trials and integrating these innovative therapies into clinical practice.
The key regions considered for the global Antibody Drug Conjugate Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Antibody Drug Conjugate Market in terms of revenue. The market growth in the region is being attributed to factors including advancements in oncology and targeted therapies. The European Union (EU) maintains a robust regulatory framework for ADCs, fostering strategic collaborations and novel therapy developments. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising R&D expenditure and the prevalence of cancer are propelling the need for ADCs. Additionally, the adoption of advanced technologies for manufacturing ADCs is anticipated to drive their utilization across end-use sectors.
Major market player included in this report are:
AbbVie Inc.
AstraZeneca PLC
Pfizer, Inc.
Roche Holding AG
GlaxoSmithKline PLC
Daiichi Sankyo Company, Limited
Seagen Inc.
ADC Therapeutics SA
ImmunoGen, Inc.
Astellas Pharma Inc.
Bayer AG
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Sorrento Therapeutics, Inc.
BioNTech SE
The detailed segments and sub-segment of the market are explained below:
By Mechanism of Action
North America
The ADC market is experiencing a significant shift towards ErbB2 antibodies (HER2) due to their effectiveness in treating breast and gastric cancer. These ADCs have shown substantial clinical success in targeting the HER2 antigen, which is overexpressed in these cancers. Drugs like Enhertu have become prominent in the oncology field for their targeted therapies, providing improved patient outcomes. The preference for ErbB2 antibodies underscores the market's focus on precision medicine and targeted treatment approaches.
Technological advancements are also shaping the ADC market, with a rising preference for linkerless technology. This technology simplifies the manufacturing process and improves the stability and homogeneity of ADCs. Linkerless ADCs directly conjugate the cytotoxic drug to the antibody, offering streamlined production and potentially enhanced therapeutic efficacy. Additionally, cleavable and non-cleavable linkers continue to play crucial roles, with each offering unique benefits in terms of stability and targeted drug release.
In terms of indications, ADCs are rapidly gaining traction for treating breast cancer. Their ability to target overexpressed receptors, such as HER2, makes them highly effective in managing this prevalent cancer type. Furthermore, ADCs are extensively used for blood cancers, lymphomas, and multiple myeloma, demonstrating their versatility in oncology. These targeted therapies are revolutionizing cancer treatment, providing new hope for patients with previously limited options.
The end-user segment for ADCs is diverse, with significant adoption in academic research institutes, biopharmaceutical and biotechnology companies, hospitals, and specialized cancer centers. Academic research institutes are essential in advancing the understanding of ADC mechanisms and exploring new therapeutic applications. Biopharmaceutical and biotechnology companies are at the forefront of ADC development, investing heavily in R&D to discover novel targets and improve drug-linker technologies. Hospitals and specialized cancer centers play pivotal roles in validating ADC efficacy through clinical trials and integrating these innovative therapies into clinical practice.
The key regions considered for the global Antibody Drug Conjugate Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Antibody Drug Conjugate Market in terms of revenue. The market growth in the region is being attributed to factors including advancements in oncology and targeted therapies. The European Union (EU) maintains a robust regulatory framework for ADCs, fostering strategic collaborations and novel therapy developments. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising R&D expenditure and the prevalence of cancer are propelling the need for ADCs. Additionally, the adoption of advanced technologies for manufacturing ADCs is anticipated to drive their utilization across end-use sectors.
Major market player included in this report are:
AbbVie Inc.
AstraZeneca PLC
Pfizer, Inc.
Roche Holding AG
GlaxoSmithKline PLC
Daiichi Sankyo Company, Limited
Seagen Inc.
ADC Therapeutics SA
ImmunoGen, Inc.
Astellas Pharma Inc.
Bayer AG
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Sorrento Therapeutics, Inc.
BioNTech SE
The detailed segments and sub-segment of the market are explained below:
By Mechanism of Action
- CD30 Antibodies
- ErbB2 Antibodies
- Adcetris
- Blenrep
- Enhertu
- Kadcyla
- Padcev
- Trodelvy
- Cleavable Linker
- Linkerless
- Non-Cleavable Linker
- Blood Cancer
- Breast Cancer
- Lymphoma
- Multiple Myeloma
- Urothelial Cancer & Bladder Cancer
- Academic Research Institutes
- Biopharmaceutical & Biotechnology Companies
- Hospitals
- Specialized Cancer Centers
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- ROE
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Brazil
- Mexico
- Saudi Arabia
- South Africa
- RoMEA
- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL ANTIBODY DRUG CONJUGATE MARKET EXECUTIVE SUMMARY
1.1. Global Antibody Drug Conjugate Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Mechanism of Action
1.3.2. By Drugs
1.3.3. By Technology
1.3.4. By Indication
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL ANTIBODY DRUG CONJUGATE MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Cancer Prevalence
3.1.2. Advancements in ADC Technologies
3.1.3. Expanding Applications Beyond Oncology
3.2. Market Challenges
3.2.1. Complexity of Manufacturing Process
3.2.2. High Costs and Regulatory Hurdles
3.3. Market Opportunities
3.3.1. Development of Eco-friendly Drugs
3.3.2. Technological Advancements in Manufacturing
3.3.3. Expansion in Emerging Markets
CHAPTER 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY MECHANISM OF ACTION 2022-2032
5.1. Segment Dashboard
5.2. Global Antibody Drug Conjugate Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. CD30 Antibodies
5.2.2. ErbB2 Antibodies
CHAPTER 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY DRUGS 2022-2032
6.1. Segment Dashboard
6.2. Global Antibody Drug Conjugate Market: Drugs Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Adcetris
6.2.2. Blenrep
6.2.3. Enhertu
6.2.4. Kadcyla
6.2.5. Padcev
6.2.6. Trodelvy
CHAPTER 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY TECHNOLOGY 2022-2032
7.1. Segment Dashboard
7.2. Global Antibody Drug Conjugate Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Cleavable Linker
7.2.2. Linkerless
7.2.3. Non-Cleavable Linker
CHAPTER 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY INDICATION 2022-2032
8.1. Segment Dashboard
8.2. Global Antibody Drug Conjugate Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Blood Cancer
8.2.2. Breast Cancer
8.2.3. Lymphoma
8.2.4. Multiple Myeloma
8.2.5. Urothelial Cancer & Bladder Cancer
CHAPTER 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY END USER 2022-2032
9.1. Segment Dashboard
9.2. Global Antibody Drug Conjugate Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Academic Research Institutes
9.2.2. Biopharmaceutical & Biotechnology Companies
9.2.3. Hospitals
9.2.4. Specialized Cancer Centers
CHAPTER 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY REGION 2022-2032
10.1. North America Antibody Drug Conjugate Market
10.1.1. U.S. Antibody Drug Conjugate Market
10.1.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.1.1.2. Drugs breakdown size & forecasts, 2022-2032
10.1.1.3. Technology breakdown size & forecasts, 2022-2032
10.1.1.4. Indication breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada Antibody Drug Conjugate Market
10.1.2.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.1.2.2. Drugs breakdown size & forecasts, 2022-2032
10.1.2.3. Technology breakdown size & forecasts, 2022-2032
10.1.2.4. Indication breakdown size & forecasts, 2022-2032
10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Drug Conjugate Market
10.2.1. U.K. Antibody Drug Conjugate Market
10.2.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.2.1.2. Drugs breakdown size & forecasts, 2022-2032
10.2.1.3. Technology breakdown size & forecasts, 2022-2032
10.2.1.4. Indication breakdown size & forecasts, 2022-2032
10.2.1.5. End User breakdown size & forecasts, 2022-2032
10.2.2. Germany Antibody Drug Conjugate Market
10.2.3. France Antibody Drug Conjugate Market
10.2.4. Spain Antibody Drug Conjugate Market
10.2.5. Italy Antibody Drug Conjugate Market
10.2.6. Rest of Europe Antibody Drug Conjugate Market
10.3. Asia-Pacific Antibody Drug Conjugate Market
10.3.1. China Antibody Drug Conjugate Market
10.3.2. India Antibody Drug Conjugate Market
10.3.3. Japan Antibody Drug Conjugate Market
10.3.4. Australia Antibody Drug Conjugate Market
10.3.5. South Korea Antibody Drug Conjugate Market
10.3.6. Rest of Asia Pacific Antibody Drug Conjugate Market
10.4. Latin America Antibody Drug Conjugate Market
10.4.1. Brazil Antibody Drug Conjugate Market
10.4.2. Mexico Antibody Drug Conjugate Market
10.4.3. Rest of Latin America Antibody Drug Conjugate Market
10.5. Middle East & Africa Antibody Drug Conjugate Market
10.5.1. Saudi Arabia Antibody Drug Conjugate Market
10.5.2. South Africa Antibody Drug Conjugate Market
10.5.3. Rest of Middle East & Africa Antibody Drug Conjugate Market
CHAPTER 11. COMPETITIVE INTELLIGENCE
11.1. Key Company SWOT Analysis
11.1.1. Company
11.1.2. Company
11.1.3. Company
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Roche Holding AG
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. GlaxoSmithKline PLC
11.3.3. Daiichi Sankyo Company, Limited
11.3.4. Seagen Inc.
11.3.5. ADC Therapeutics SA
11.3.6. ImmunoGen, Inc.
11.3.7. Astellas Pharma Inc.
11.3.8. Bayer AG
11.3.9. Takeda Pharmaceutical Company Limited
11.3.10. Sanofi S.A.
11.3.11. Sorrento Therapeutics, Inc.
11.3.12. BioNTech SE
11.3.13. AbbVie Inc.
11.3.14. AstraZeneca PLC
11.3.15. Pfizer, Inc.
CHAPTER 12. RESEARCH PROCESS
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
1.1. Global Antibody Drug Conjugate Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Mechanism of Action
1.3.2. By Drugs
1.3.3. By Technology
1.3.4. By Indication
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL ANTIBODY DRUG CONJUGATE MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Cancer Prevalence
3.1.2. Advancements in ADC Technologies
3.1.3. Expanding Applications Beyond Oncology
3.2. Market Challenges
3.2.1. Complexity of Manufacturing Process
3.2.2. High Costs and Regulatory Hurdles
3.3. Market Opportunities
3.3.1. Development of Eco-friendly Drugs
3.3.2. Technological Advancements in Manufacturing
3.3.3. Expansion in Emerging Markets
CHAPTER 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY MECHANISM OF ACTION 2022-2032
5.1. Segment Dashboard
5.2. Global Antibody Drug Conjugate Market: Mechanism of Action Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. CD30 Antibodies
5.2.2. ErbB2 Antibodies
CHAPTER 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY DRUGS 2022-2032
6.1. Segment Dashboard
6.2. Global Antibody Drug Conjugate Market: Drugs Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Adcetris
6.2.2. Blenrep
6.2.3. Enhertu
6.2.4. Kadcyla
6.2.5. Padcev
6.2.6. Trodelvy
CHAPTER 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY TECHNOLOGY 2022-2032
7.1. Segment Dashboard
7.2. Global Antibody Drug Conjugate Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Cleavable Linker
7.2.2. Linkerless
7.2.3. Non-Cleavable Linker
CHAPTER 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY INDICATION 2022-2032
8.1. Segment Dashboard
8.2. Global Antibody Drug Conjugate Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Blood Cancer
8.2.2. Breast Cancer
8.2.3. Lymphoma
8.2.4. Multiple Myeloma
8.2.5. Urothelial Cancer & Bladder Cancer
CHAPTER 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY END USER 2022-2032
9.1. Segment Dashboard
9.2. Global Antibody Drug Conjugate Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Academic Research Institutes
9.2.2. Biopharmaceutical & Biotechnology Companies
9.2.3. Hospitals
9.2.4. Specialized Cancer Centers
CHAPTER 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE & FORECASTS BY REGION 2022-2032
10.1. North America Antibody Drug Conjugate Market
10.1.1. U.S. Antibody Drug Conjugate Market
10.1.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.1.1.2. Drugs breakdown size & forecasts, 2022-2032
10.1.1.3. Technology breakdown size & forecasts, 2022-2032
10.1.1.4. Indication breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada Antibody Drug Conjugate Market
10.1.2.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.1.2.2. Drugs breakdown size & forecasts, 2022-2032
10.1.2.3. Technology breakdown size & forecasts, 2022-2032
10.1.2.4. Indication breakdown size & forecasts, 2022-2032
10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Drug Conjugate Market
10.2.1. U.K. Antibody Drug Conjugate Market
10.2.1.1. Mechanism of Action breakdown size & forecasts, 2022-2032
10.2.1.2. Drugs breakdown size & forecasts, 2022-2032
10.2.1.3. Technology breakdown size & forecasts, 2022-2032
10.2.1.4. Indication breakdown size & forecasts, 2022-2032
10.2.1.5. End User breakdown size & forecasts, 2022-2032
10.2.2. Germany Antibody Drug Conjugate Market
10.2.3. France Antibody Drug Conjugate Market
10.2.4. Spain Antibody Drug Conjugate Market
10.2.5. Italy Antibody Drug Conjugate Market
10.2.6. Rest of Europe Antibody Drug Conjugate Market
10.3. Asia-Pacific Antibody Drug Conjugate Market
10.3.1. China Antibody Drug Conjugate Market
10.3.2. India Antibody Drug Conjugate Market
10.3.3. Japan Antibody Drug Conjugate Market
10.3.4. Australia Antibody Drug Conjugate Market
10.3.5. South Korea Antibody Drug Conjugate Market
10.3.6. Rest of Asia Pacific Antibody Drug Conjugate Market
10.4. Latin America Antibody Drug Conjugate Market
10.4.1. Brazil Antibody Drug Conjugate Market
10.4.2. Mexico Antibody Drug Conjugate Market
10.4.3. Rest of Latin America Antibody Drug Conjugate Market
10.5. Middle East & Africa Antibody Drug Conjugate Market
10.5.1. Saudi Arabia Antibody Drug Conjugate Market
10.5.2. South Africa Antibody Drug Conjugate Market
10.5.3. Rest of Middle East & Africa Antibody Drug Conjugate Market
CHAPTER 11. COMPETITIVE INTELLIGENCE
11.1. Key Company SWOT Analysis
11.1.1. Company
11.1.2. Company
11.1.3. Company
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Roche Holding AG
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. GlaxoSmithKline PLC
11.3.3. Daiichi Sankyo Company, Limited
11.3.4. Seagen Inc.
11.3.5. ADC Therapeutics SA
11.3.6. ImmunoGen, Inc.
11.3.7. Astellas Pharma Inc.
11.3.8. Bayer AG
11.3.9. Takeda Pharmaceutical Company Limited
11.3.10. Sanofi S.A.
11.3.11. Sorrento Therapeutics, Inc.
11.3.12. BioNTech SE
11.3.13. AbbVie Inc.
11.3.14. AstraZeneca PLC
11.3.15. Pfizer, Inc.
CHAPTER 12. RESEARCH PROCESS
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Antibody Drug Conjugate market, report scope
TABLE 2. Global Antibody Drug Conjugate market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Antibody Drug Conjugate market estimates & forecasts by Mechanism of Action 2022-2032 (USD Billion)
TABLE 4. Global Antibody Drug Conjugate market estimates & forecasts by Drugs 2022-2032 (USD Billion)
TABLE 5. Global Antibody Drug Conjugate market estimates & forecasts by Technology 2022-2032 (USD Billion)
TABLE 6. Global Antibody Drug Conjugate market estimates & forecasts by Indication 2022-2032 (USD Billion)
TABLE 7. Global Antibody Drug Conjugate market estimates & forecasts by End User 2022-2032 (USD Billion)
TABLE 8. Global Antibody Drug Conjugate market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Antibody Drug Conjugate market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. U.S. Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. U.S. Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 12. Canada Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Canada Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 14. U.K. Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.K. Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 16. Germany Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 17. Germany Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. France Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. France Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Spain Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
.....
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
TABLE 1. Global Antibody Drug Conjugate market, report scope
TABLE 2. Global Antibody Drug Conjugate market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Antibody Drug Conjugate market estimates & forecasts by Mechanism of Action 2022-2032 (USD Billion)
TABLE 4. Global Antibody Drug Conjugate market estimates & forecasts by Drugs 2022-2032 (USD Billion)
TABLE 5. Global Antibody Drug Conjugate market estimates & forecasts by Technology 2022-2032 (USD Billion)
TABLE 6. Global Antibody Drug Conjugate market estimates & forecasts by Indication 2022-2032 (USD Billion)
TABLE 7. Global Antibody Drug Conjugate market estimates & forecasts by End User 2022-2032 (USD Billion)
TABLE 8. Global Antibody Drug Conjugate market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Antibody Drug Conjugate market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. U.S. Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. U.S. Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 12. Canada Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Canada Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 14. U.K. Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.K. Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 16. Germany Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 17. Germany Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. France Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. France Antibody Drug Conjugate market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Spain Antibody Drug Conjugate market estimates & forecasts, 2022-2032 (USD Billion)
.....
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
LIST OF FIGURES
FIG 1. Global Antibody Drug Conjugate market, research methodology
FIG 2. Global Antibody Drug Conjugate market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Antibody Drug Conjugate market, key trends 2023
FIG 5. Global Antibody Drug Conjugate market, growth prospects 2022-2032
FIG 6. Global Antibody Drug Conjugate market, porters 5 force model
FIG 7. Global Antibody Drug Conjugate market, PESTEL analysis
FIG 8. Global Antibody Drug Conjugate market, value chain analysis
FIG 9. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Antibody Drug Conjugate market, regional snapshot 2022 & 2032
FIG 15. North America Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 16. Europe Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 18. Latin America Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 20. Global Antibody Drug Conjugate market, company market share analysis (2023)
.....
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
FIG 1. Global Antibody Drug Conjugate market, research methodology
FIG 2. Global Antibody Drug Conjugate market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Antibody Drug Conjugate market, key trends 2023
FIG 5. Global Antibody Drug Conjugate market, growth prospects 2022-2032
FIG 6. Global Antibody Drug Conjugate market, porters 5 force model
FIG 7. Global Antibody Drug Conjugate market, PESTEL analysis
FIG 8. Global Antibody Drug Conjugate market, value chain analysis
FIG 9. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Antibody Drug Conjugate market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Antibody Drug Conjugate market, regional snapshot 2022 & 2032
FIG 15. North America Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 16. Europe Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 18. Latin America Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Antibody Drug Conjugate market 2022 & 2032 (USD Billion)
FIG 20. Global Antibody Drug Conjugate market, company market share analysis (2023)
.....
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
